{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreicvp7gh4yado5ukvktgl646wyw7ilxkto673pgg4vqakcjsxz7iga",
    "uri": "at://did:plc:2gbt2dlwaqovtnmxkat3tyke/app.bsky.feed.post/3mpadrpizsuq2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiazhvzyoehzzfxlpme5tqowlxlqzfmcw74epovajqupepbpbvxocm"
    },
    "mimeType": "image/jpeg",
    "size": 189595
  },
  "path": "/articles/d41586-026-01976-w",
  "publishedAt": "2026-06-27T01:49:23.999Z",
  "site": "https://www.nature.com",
  "tags": [
    "doi:10.1038/d41586-026-01976-w"
  ],
  "textContent": "Nature, Published online: 26 June 2026; doi:10.1038/d41586-026-01976-w\n\nA handful of start-up firms are testing therapies that target specific epigenetic markers to treat everything from high cholesterol to a rare muscular disorder.",
  "title": "CRISPR’s next act: the companies editing the epigenome to treat disease",
  "updatedAt": "2026-06-26T00:00:00.000Z"
}